Blumenthal Cancer Center

Charlotte, North Carolina 28231

0 studies enrolling now · 17 studies all time

What they study most

Aging, Cervical Cancer, Clear-cell Metastatic Renal Cell Carcinoma, Cognition, Endometrial Cancer, Fallopian Tube Cancer, Malignant Metastatic Melanoma, Melanoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

Studies at this site

• BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) — Completed
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) — Completed
• PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy — Completed
• Cognition in the Study of Tamoxifen and Raloxifene — Completed
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed
• Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) — Completed
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma — Completed
• A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer — Completed
• Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer — Stopped early
• ChemoFx® PRO - A Post-Market Data Collection Study — Stopped early
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
• TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer — Completed
• Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma — Completed
• Clinical Trial for Ovarian Cancer (OvaRex®) — Stopped early
• Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer — Completed
• A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer — Completed